Energex Systems' HemoModulation(TM) therapy is an extracorporeal treatment that involves exposing a small amount of an infected subject's blood (3-4%) to a precise amount of ultra-violet light (UV), for a precise amount of time. During the process, any pathogen in the blood that is directly exposed to the UV energy is inactivated. After exposure, the blood carrying the inactive pathogen is returned to the patient through the same portal it was drawn from. The hypothesis is that UV-inactivated virus will serve as an autologous vaccine and stimulate the patient's immune system against their own strain of virus. The treatment process takes 20-30 minutes. An animation of the procedure can be viewed at
http://www.energexsystems.com/hemomod.htm
Main Site
http://www.marketwatch.com/news/story/fda-approves-energex-systems-inc/story.aspx?guid=%7B7E9D38FC-2D96-48BD-BA48-C1584995CAFC%7D&dist=hppr